ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO
PHILADELPHIA, PA, 21 December 2010 – ERT, a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, today confirmed that the effective date of the previously announced retirement of Dr. Michael J. McKelvey, its President and CEO, is December 21, 2010.
Dr. Joel Morganroth, currently ERT’s Chairman and Chief Scientific Officer, has also been elected by the Board as President and CEO until ERT hires a permanent CEO. Dr. Morganroth has served as the Chairman of ERT’s Board of Directors since 1999 and as Chief Scientific Officer since April 2006. He previously served as the company’s Chief Executive Officer from 1993 to March 2001 and also has consulted for ERT since 1977. Dr. Morganroth is also a globally recognized cardiologist and clinical researcher and has had more than 10 years’ experience as a medical review officer/expert for the U.S. Food and Drug Administration (FDA).
Dr. Morganroth commented, “We thank Dr. McKelvey for his years of service and wish him well in his future endeavors.”
“ERT is a leading provider of innovative solutions and is well positioned for continued growth. In my expanded role, I will continue to leverage my experience and knowledge of the organization and domain expertise to strengthen our position in clinical research associated with Cardiac Safety, Respiratory and electronic Patient Reported Outcomes [ePRO]. With our superb management team, we will continue our goal of enhanced growth through the exciting development of adjacent markets.”
For further press information please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email email@example.com .
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
The Scott Partnership
Tel: +44 1477 539539
+1 215 972 0420